H-E-B, RediClinic open largest U.S. retail clinic in Houston area
HOUSTON Clinic operator RediClinic has opened its 15th Houston-area convenient care clinic in the new H-E-B store that, according to the Convenient Care Association, is the largest retail-based clinic in the United States.
The 926-square-foot clinic features three exam rooms and a room specifically for blood draws.
“We are delighted to be expanding out footprint in our home market with the opening of our 15th Greater Houston clinic,” said Web Golinkin, chief executive officer of RediClinic. “The larger clinic design in H-E-B’s new Bunker Hill store enables us to treat more patients and gives us more flexibility in adding new services.”
RediClinic operates 21 clinics in H-E-B stores in Houston and Austin; and 15 clinics in Wal-Mart stores in Atlanta, Ga.; Fayetteville and Rogers, Ark.; Richmond, Va.; and Tulsa, Okla.
FDA approves Mylan’s generic drug for treating epilepsy
ROCKVILLE, Md. The Food and Drug Administration has approved Mylan’s levetiracetam tablets, FDA records show.
The tablets, a generic version of UCB’s epilepsy drug Keppra, will be available in 250 mg, 500 mg and 750 mg dosages.
The agency’s records indicate an approval date of Nov. 4 and that Mylan’s is the first generic version of Keppra.
Study shows Gardasil is effective in prevention of HPV in males
ATLANTA A vaccine used to prevent genital warts in girls and women works in boys and men, too.
A study of Gardasil funded by its manufacturer, Merck, has shown that the vaccine is effective in preventing infection human papillomavirus in boys and men as well as in girls and women. The study took place in 20 countries among 4,000 boys and men aged 16 to 26, including more than 1,000 in the United States.
Regulatory agencies in 40 countries have approved Gardasil for use in males, but not the Food and Drug Administration, which has approved it only for females aged 9 to 26 because of the lack of evidence of efficacy in males.
Now, however, Merck plans to ask the FDA to extend approval to males. As yet, there is no evidence that the vaccine prevents HPV-related cancers in males.